Wojciech Jurczak

ASCEND Phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2158)

Wojciech Jurczak

Click the following button to download this presentation’s slides